Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer

Abstract

The advancements in early stratification and timely evaluation of therapeutic effects have revolutionized the ability to assess curative outcomes promptly. The separation between diagnosis/treatment and timely assessment of treatment response, along with delays in evaluating therapy efficacy, are significant contributors to treatment failures. Traditional approaches for evaluating curative effects face challenges posed by tumor heterogeneity and resistance, making it challenging to determine the effectiveness of a given therapeutic regimen at an early stage in clinical practice. However, molecular imaging using activatable probes has overcome these obstacles and transformed the field by shifting focus towards developing functional probes for visualizing tumors as well as enabling early stratification or timely evaluation of therapy effects. In this article, we emphasize the importance of diverse activatable molecular imaging probes and provide insights into early stratification or timely evaluation of various therapies’ effects. Finally, we discuss the challenges faced in this field and propose future research directions.

Keywords

activatable probe / biomarker / early stratification / molecular imaging / therapy effect / timely evaluation

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71 (2021): 209-249.

[2] L. Lin, S. Wang, H. Deng, et al., “Endogenous Labile Iron Pool-Mediated Free Radical Generation for Cancer Chemodynamic Therapy,” Journal of the American Chemical Society 142 (2020): 15320.

[3] S. Y. Qin, A. Q. Zhang, and X. Z. Zhang, “Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines,” Small 14 (2018): e1802417.

[4] G. Wei, Y. Wang, G. Yang, Y. Wang, and R. Ju, “Recent Progress in Nanomedicine for Enhanced Cancer Chemotherapy,” Theranostics 11 (2021): 6370.

[5] S. Her, D. A. Jaffray, and C. Allen, “Gold Nanoparticles for Applications in Cancer Radiotherapy: Mechanisms and Recent Advancements,” Advanced Drug Delivery Reviews 109 (2017): 84.

[6] W. Fu, X. Zhang, L. Mei, et al., “Stimuli-Responsive Small-on-Large Nanoradiosensitizer for Enhanced Tumor Penetration and Radiotherapy Sensitization,” ACS Nano 14 (2020): 10001.

[7] J. Fang, Y. Zhao, A. Wang, et al., “In Vivo Quantitative Assessment of a Radiation Dose Based on Ratiometric Photoacoustic Imaging of Tumor Apoptosis,” Analytical Chemistry 94 (2022): 5149.

[8] L. Wang, W. Jiang, L. Xiao, et al., “Self-Reporting and Splitting Nanopomegranates Potentiate Deep Tissue Cancer Radiotherapy via Elevated Diffusion and Transcytosis,” ACS Nano 14 (2020): 8459.

[9] H. Deng, W. Yang, Z. Zhou, et al., “Targeted Scavenging of Extracellular ROS Relieves Suppressive Immunogenic Cell Death,” Nature Communications 11 (2020): 4951.

[10] N. Gong, Y. Zhang, X. Teng, et al., “Proton-Driven Transformable Nanovaccine for Cancer Immunotherapy,” Nature Nanotechnology 15 (2020): 1053.

[11] M. Chang, Z. Hou, M. Wang, et al., “Single-Atom Pd Nanozyme for Ferroptosis-Boosted Mild-Temperature Photothermal Therapy,” Angewandte Chemie, International Edition 60 (2021): 12971.

[12] H. Wang, J. Chang, M. Shi, W. Pan, N. Li, and B. Tang, “A Dual-Targeted Organic Photothermal Agent for Enhanced Photothermal Therapy,” Angewandte Chemie, International Edition 58 (2019): 1057.

[13] Y. Wan, L. H. Fu, C. Li, J. Lin, and P. Huang, “Conquering the Hypoxia Limitation for Photodynamic Therapy,” Advanced Materials 33 (2021): e2103978.

[14] D. Ni, C. A. Ferreira, T. E. Barnhart, et al., “Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy,” Journal of the American Chemical Society 140 (2018): 14971.

[15] W. Sang, Z. Zhang, Y. Dai, and X. Chen, “Recent Advances in Nanomaterial-Based Synergistic Combination Cancer Immunotherapy,” Chemical Society Reviews 48 (2019): 3771.

[16] Y. Wu, L. Su, M. Yuan, et al., “In Vivo X-Ray Triggered Catalysis of H 2 Generation for Cancer Synergistic Gas Radiotherapy,” Angewandte Chemie International Edition 60 (2021): 12868.

[17] G. Liu, J. Zhu, H. Guo, et al., “Mo 2 C-Derived Polyoxometalate for NIR-II Photoacoustic Imaging-Guided Chemodynamic/Photothermal Synergistic Therapy,” Angewandte Chemie International Edition 58 (2019): 18641.

[18] L. Wu, Y. Ishigaki, W. Zeng, et al., “Generation of Hydroxyl Radical-Activatable Ratiometric Near-Infrared Bimodal Probes for Early Monitoring of Tumor Response to Therapy,” Nature Communications 12 (2021): 6145.

[19] J. Ouyang, A. Xie, J. Zhou, et al., “Minimally Invasive Nanomedicine: Nanotechnology in Photo-/Ultrasound-/Radiation-/Magnetism-Mediated Therapy and Imaging,” Chemical Society Reviews 51, no. 12 (2022): 4996-5041, https://doi.org/10.1039/D1CS01148K.

[20] M. Krause, A. Dubrovska, A. Linge, and M. Baumann, “Cancer Stem Cells: Radioresistance, Prediction of Radiotherapy Outcome and Specific Targets for Combined Treatments,” Advanced Drug Delivery Reviews 109 (2017): 63.

[21] R. Xie, S. Ruan, J. Liu, et al., “Furin-Instructed Aggregated Gold Nanoparticles for Re-Educating Tumor Associated Macrophages and Overcoming Breast Cancer Chemoresistance,” Biomaterials 275 (2021): 120891.

[22] S. K. Paidi, P. M. Diaz, S. Dadgar, et al., “Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment,” Cancer Research 79 (2019): 2054.

[23] S. B. Balmukhanov, M. L. Yefimov, and T. S. Kleinbock, “Aquired Radioresistance of Tumour Cells,” Nature 216 (1967): 709.

[24] F. Ahmad, X. Wang, Z. Jiang, et al., “Codoping Enhanced Radioluminescence of Nanoscintillators for X-Ray-Activated Synergistic Cancer Therapy and Prognosis Using Metabolomics,” ACS Nano 13 (2019): 10419.

[25] A. G. Sorace, A. A. Elkassem, S. J. Galgano, et al., “Imaging for Response Assessment in Cancer Clinical Trials,” Seminars in Nuclear Medicine 50 (2020): 488.

[26] B. B. Kasten, N. Udayakumar, J. W. Leavenworth, et al., “Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology,” Theranostics 9 (2019): 5085.

[27] M. R. Horsman, L. S. Mortensen, J. B. Petersen, M. Busk, and J. Overgaard, “Imaging Hypoxia to Improve Radiotherapy Outcome,” Nature Reviews Clinical Oncology 9 (2012): 674.

[28] B. R. Smith and S. S. Gambhir, “Nanomaterials for in Vivo Imaging,” Chemical Review 117 (2017): 901.

[29] Q. Fu, X. Yang, M. Wang, K. Zhu, Y. Wang, and J. Song, “Activatable Probes for Ratiometric Imaging of Endogenous Biomarkers in Vivo,” ACS Nano 18 (2024): 3916.

[30] X. Yang, C. Li, P. Li, and Q. Fu, “Ratiometric Optical Probes for Biosensing,” Theranostics 13 (2023): 2632.

[31] P. Zhang, W. Li, C. Liu, et al., “Molecular Imaging of Tumour-Associated Pathological Biomarkers with Smart Nanoprobe: From “Seeing” to “Measuring”,” Exploration 3 (2023): 20230070.

[32] R. van der Meel, E. Sulheim, Y. Shi, F. Kiessling, W. J. M. Mulder, and T. Lammers, “Smart Cancer Nanomedicine,” Nature Nanotechnology 14 (2019): 1007.

[33] M. Wu, Y. Zhang, Y. Zhang, Y. Liu, M. Wu, and Z. Ye, “Imaging-Based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response,” Radiol Imaging Cancer 1 (2019): e190031.

[34] B. A. Moffat, T. L. Chenevert, T. S. Lawrence, et al., “Functional Diffusion Map: A Noninvasive MRI Biomarker for Early Stratification of Clinical Brain Tumor Response,” Proceedings National Academy of Science of the United States of America 102 (2005): 5524.

[35] X. Bao, M. W. Wang, J. M. Luo, S. Y. Wang, Y. P. Zhang, and Y. J. Zhang, “Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters,” Theranostics 6 (2016): 2084.

[36] C. Shi, Z. Zhou, H. Lin, and J. Gao, “Imaging Beyond Seeing: Early Prognosis of Cancer Treatment,” Small Methods 5 (2021): e2001025.

[37] H. Liu, C. Lu, L. Han, X. Zhang, and G. Song, “Optical—Magnetic Probe for Evaluating Cancer Therapy,” Coordination Chemistry Reviews 441 (2021): 213978.

[38] C. Zhang, J. Li, C. Lu, et al., “H 2 S-Activated “One-Key Triple-Lock” Bis-Metal Coordination Network for Visualizing Precise Therapy of Colon Cancer,” CCS Chemistry 3 (2021): 2126.

[39] Y. Wang, L. Shi, Z. Ye, et al., “Reactive Oxygen Correlated Chemiluminescent Imaging of a Semiconducting Polymer Nanoplatform for Monitoring Chemodynamic Therapy,” Nano Letters 20 (2020): 176.

[40] C. Lu, C. Zhang, P. Wang, et al., “Light-Free Generation of Singlet Oxygen through Manganese-Thiophene Nanosystems for pH-Responsive Chemiluminescence Imaging and Tumor Therapy,” Chemistry 6 (2020): 2314.

[41] X. Ge, L. Su, Z. Chen, et al., “A Radio-Pharmaceutical Fluorescent Probe for Synergistic Cancer Radiotherapy and Ratiometric Imaging of Tumor Reactive Oxygen Species,” Angewandte Chemie International Edition 2023, 62, e202305744.

[42] L. Su, Y. Chen, H. Huo, et al., “NIR-II Ratiometric Chemiluminescent/Fluorescent Reporters for Real-Time Monitoring and Evaluating Cancer Photodynamic Therapy Efficacy,” Small 18 (2022): 2202551.

[43] L. J. Rich, A. Miller, A. K. Singh, and M. Seshadri, “Photoacoustic Imaging as an Early Biomarker of Radio Therapeutic Efficacy in Head and Neck Cancer,” Theranostics 8 (2018): 2064.

[44] R. Popovtzer, A. Agrawal, N. A. Kotov, et al., “Targeted Gold Nanoparticles Enable Molecular CT Imaging of Cancer,” Nano Letters 8 (2008): 4593.

[45] Z. Jiang, M. Zhang, P. Li, Y. Wang, and Q. Fu, “Nanomaterial-Based CT Contrast Agents and Their Applications in Image-Guided Therapy,” Theranostics 13 (2023): 483.

[46] L. Schenkman, “Second Thoughts About CT Imaging,” Science 331 (2011): 1002.

[47] D. Tsvirkun, Y. Ben-Nun, E. Merquiol, et al., “CT Imaging of Enzymatic Activity in Cancer Using Covalent Probes Reveal a Size-Dependent Pattern,” Journal of the American Chemical Society 140 (2018): 12010.

[48] R. Meir, K. Shamalov, T. Sadan, et al., “Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy,” ACS Nano 11 (2017): 11127.

[49] D. Ni, E. B. Ehlerding, and W. Cai, “Multimodality Imaging Agents with PET as the Fundamental Pillar,” Angewandte Chemie, International Edition 58 (2019): 2570.

[50] S. L. Pimlott and A. Sutherland, “Molecular Tracers for the PET and SPECT Imaging of Disease,” Chemical Society Reviews 40 (2011): 149.

[51] C. Wu, F. Li, G. Niu, and X. Chen, “PET Imaging of Inflammation Biomarkers,” Theranostics 3 (2013): 448.

[52] S. M. Ametamey, “Molecular Imaging with PET,” Chemical Reviews 108 (2008): 4036.

[53] S. M. Ametamey, M. Honer, and P. A. Schubiger, “Molecular Imaging with PET,” CCS Chemistry 108 (2008): 1501.

[54] A. W. Woodham, S. H. Zeigler, E. L. Zeyang, et al., “In Vivo Detection of Antigen-Specific CD8+ T Cells by Immuno-Positron Emission Tomography,” Nature Methods 17 (2020): 1025.

[55] I. S. Alam, A. T. Mayer, I. Sagiv-Barfi, et al., “Imaging Activated T Cells Predicts Response to Cancer Vaccines,” Journal of Clinical Investigation 128 (2018): 2569.

[56] C. Perez-Medina, D. Abdel-Atti, J. Tang, et al., “Nanoreporter PET Predicts the Efficacy of Anti-Cancer Nanotherapy,” Nature Communications 7 (2016): 11838.

[57] J. Huang and K. Pu, “Activatable Molecular Probes for Second Near-Infrared Fluorescence, Chemiluminescence, and Photoacoustic Imaging,” Angewandte Chemie, International Edition 59 (2020): 11717.

[58] B. M. Larimer, E. Wehrenberg-Klee, F. Dubois, et al., “Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response,” Cancer Research 77 (2017): 2318.

[59] M. Tan and Z. R. Lu, “Integrin Targeted MR Imaging,” Theranostics 1 (2011): 83.

[60] J. Wahsner, E. M. Gale, A. Rodriguez-Rodriguez, and P. Caravan, “Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers,” CCS Chemistry 119 (2019): 957.

[61] M. Wang, Y. Wang, and Q. Fu, “Magneto-optical Nanosystems for Tumor Multimodal Imaging and Therapy In-Vivo,” Mater Today Bio 26 (2024): 101027.

[62] Q. Fu, H. Feng, L. Liu, et al., “Spatiotemporally Controlled Formation and Rotation of Magnetic Nanochains In Vivo for Precise Mechanotherapy of Tumors,” Angewandte Chemie, International Edition 2022, 61, e202213319.

[63] Q. Fu, Z. Li, J. Ye, et al., “Magnetic Targeted Near-Infrared II PA/MR Imaging Guided Photothermal Therapy to Trigger Cancer Immunotherapy,” Theranostics 10 (2020): 4997.

[64] C. Nicolescu, A. Schilb, J. Kim, et al., “Evaluating Dual-Targeted ECO/siRNA Nanoparticles against an Oncogenic lncRNA for Triple Negative Breast Cancer Therapy with Magnetic Resonance Molecular Imaging,” Chemical & Biomedical Imaging 1, no. 5 (2023): 461.

[65] M. A. Miller, S. Gadde, C. Pfirschke, et al., “Predicting Therapeutic Nanomedicine Efficacy Using a Companion Magnetic Resonance Imaging Nanoparticle,” Science Translational Medicine 7 (2015): 314ra183.

[66] A. J. Grippin, B. Wummer, T. Wildes, et al., “Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging,” ACS Nano 13 (2019): 13884.

[67] Z. Zhou, H. Deng, W. Yang, et al., “Early Stratification of Radiotherapy Response by Activatable Inflammation Magnetic Resonance Imaging,” Nature Communications 11 (2020): 3032.

[68] J. Liu, H. Cabral, B. Song, et al., “Nanoprobe-Based Magnetic Resonance Imaging of Hypoxia Predicts Responses to Radiotherapy, Immunotherapy, and Sensitizing Treatments in Pancreatic Tumors,” ACS Nano 15 (2021): 13526.

[69] X. Li, Y. Liu, X. Qi, et al., “Sensitive Activatable Nanoprobes for Real-Time Ratiometric Magnetic Resonance Imaging of Reactive Oxygen Species and Ameliorating Inflammation in Vivo,” Advanced Materials 34 (2022): e2109004.

[70] S. Wang, W. X. Ren, J. T. Hou, et al., “Fluorescence Imaging of Pathophysiological Microenvironments,” Chemical Society Reviews 2021, 50, 8887.

[71] E. Ximendes, A. Benayas, D. Jaque, and R. Marin, “Quo Vadis, Nanoparticle-Enabled in Vivo Fluorescence Imaging?,” ACS Nano 15 (2021): 1917.

[72] X. Qian and Z. Xu, “Fluorescence Imaging of Metal Ions Implicated in Diseases,” Chemical Society Reviews 44 (2015): 4487.

[73] K. Wanderi and Z. Cui, “Organic Fluorescent Nanoprobes with NIR-IIb Characteristics for Deep Learning,” Exploration 2 (2022): 20210097.

[74] C. Yang, C. Jiang, M. Yang, et al., “NAD(P)H Activated Fluorescent Probe for Rapid Intraoperative Pathological Diagnosis and Tumor Histological Grading,” Chemical & Biomedical Imaging 1, no. 8 (2023): 738.

[75] Z. Lei and F. Zhang, “Molecular Engineering of NIR-II Fluorophores for Improved Biomedical Detection,” Angewandte Chemie International Edition 60 (2021): 16294.

[76] S. Y. Ong, C. Zhang, X. Dong, and S. Q. Yao, “Recent Advances in Polymeric Nanoparticles for Enhanced Fluorescence and Photoacoustic Imaging,” Angewandte Chemie, International Edition 60 (2021): 17797.

[77] A. Kulkarni, P. Rao, S. Natarajan, et al., “Reporter Nanoparticle That Monitors Its Anticancer Efficacy in Real Time,” Proceedings National Academy of Science United State of America 113 (2016): E2104.

[78] S. Y. Li, H. Cheng, B. R. Xie, et al., “A Ratiometric Theranostic Probe for Tumor Targeting Therapy and Self-Therapeutic Monitoring,” Biomaterials 104 (2016): 297.

[79] S. He, J. Li, Y. Lyu, J. Huang, and K. Pu, “Near-Infrared Fluorescent Macromolecular Reporters for Real-Time Imaging and Urinalysis of Cancer Immunotherapy,” Journal of the American Chemical Society 142 (2020): 7075.

[80] B. Li, H. Liu, Y. He, et al., “A “Self-Checking” pH/Viscosity-Activatable NIR-II Molecule for Real-Time Evaluation of Photothermal Therapy Efficacy,” Angewandte Chemie International Edition 61 (2022): e202200025.

[81] Q. Yin, A. Pan, B. Chen, et al., “Quantitative Imaging of Intracellular Nanoparticle Exposure Enables Prediction of Nanotherapeutic Efficacy,” Nature Communications 12 (2021): 2385.

[82] A. Nguyen, A. Ramesh, S. Kumar, et al., “Granzyme B Nanoreporter for Early Monitoring of Tumor Response to Immunotherapy,” Science Advances 6 (2020): eabc2777.

[83] Y. Wang, W. Du, T. Zhang, et al., “A Self-Evaluating Photothermal Therapeutic Nanoparticle,” ACS Nano 14 (2020): 9585.

[84] X. Huang, J. Song, B. C. Yung, X. Huang, Y. Xiong, and X. Chen, “Ratiometric Optical Nanoprobes Enable Accurate Molecular Detection and Imaging,” Chemical Society Reviews 47 (2018): 2873.

[85] C. Xie, X. Zhen, Q. Miao, Y. Lyu, and K. Pu, “Self-Assembled Semiconducting Polymer Nanoparticles for Ultrasensitive Near-Infrared Afterglow Imaging of Metastatic Tumors,” Advanced Materials 30 (2018): 1801331.

[86] J. Zhu, W. Chen, L. Yang, et al., “A Self-Sustaining Near-Infrared Afterglow Chemiluminophore for High-Contrast Activatable Imaging,” Angewandte Chemie International Edition 63 (2024): e202318545.

[87] X. Li, C. Yin, S. S. Liew, C. S. Lee, and K. Pu, “Organic Semiconducting Luminophores for Near-Infrared Afterglow, Chemiluminescence, and Bioluminescence Imaging,” Advanced Functional Materials 31 (2021): 2106154.

[88] L. Yang, S. Gai, H. Ding, D. Yang, L. Feng, and P. Yang, “Recent Progress in Inorganic Afterglow Materials: Mechanisms, Persistent Luminescent Properties, Modulating Methods, and Bioimaging Applications,” Advanced Optical Materials 11 (2023): 2202382.

[89] Y. Liu, L. Teng, Y. Lyu, G. Song, X.-B. Zhang, and W. Tan, “Ratiometric Afterglow Luminescent Nanoplatform Enables Reliable Quantification and Molecular Imaging,” Nature Communications 13 (2022): 2216.

[90] C. Chen, H. Gao, H. Ou, et al., “Amplification of Activated Near-Infrared Afterglow Luminescence by Introducing Twisted Molecular Geometry for Understanding Neutrophil-Involved Diseases,” Journal of the American Chemical Society 144 (2022): 3429.

[91] Y. Li, D. He, Q. Zheng, et al., “Single-Component Photochemical Afterglow Near-Infrared Luminescent Nano-Photosensitizers: Bioimaging and Photodynamic Therapy,” Advanced Healthcare Materials 13 (2024): 2304392, https://doi.org/10.1002/adhm.202304392.

[92] Z. Li, N. Yu, J. Zhou, et al., “Afterglow Nanoparticles: Coloring Afterglow Nanoparticles for High-Contrast Time-Gating-Free Multiplex Luminescence Imaging,” Advanced Materials 32 (2020): 2070371.

[93] Y. Wang, G. Song, S. Liao, et al., “Cyclic Amplification of the Afterglow Luminescent Nanoreporter Enables the Prediction of Anti-Cancer Efficiency,” Angewandte Chemie, International Edition 60 (2021): 19779.

[94] Y. Wang, Y. Hu, and D. Ye, “Activatable Multimodal Probes for In Vivo Imaging and Theranostics,” Angewandte Chemie, International Edition 61 (2022): e202209512.

[95] A. Louie, “Multimodality Imaging Probes: Design and Challenges,” Chemical Review 110 (2010): 3146.

[96] D. Ni, E. B. Ehlerding, and W. Cai, “Multimodality Imaging Agents with PET as the Fundamental Pillar,” Angewandte Chemie, International Edition 58 (2018): 2570.

[97] G. Song, X. Zheng, Y. Wang, X. Xia, S. Chu, and J. Rao, “A Magneto-Optical Nanoplatform for Multimodality Imaging of Tumors in Mice,” ACS Nano 13 (2019): 7750.

[98] Q. Fu, Z. Li, F. Fu, X. Chen, J. Song, and H. Yang, “Stimuli-Responsive Plasmonic Assemblies and Their Biomedical Applications,” Nano Today 36 (2021): 101014.

[99] Q. Fu, H. Feng, L. Su, et al., “An Activatable Hybrid Organic-Inorganic Nanocomposite as Early Evaluation System of Therapy Effect,” Angewandte Chemie International Edition 61 (2022): e202112237.

[100] L. Wu, Y. Ishigaki, W. Zeng, et al., “Generation of Hydroxyl Radical-Activatable Ratiometric Near-Infrared Bimodal Probes for Early Monitoring of Tumor Response to Therapy,” Nature Communications 12 (2021): 6145.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.